FINAL Roivant Logo_Transparent.png
Roivant to Present at Upcoming Investor Conferences
January 25, 2022 16:30 ET | Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at two upcoming...
FINAL Roivant Logo_Transparent.png
Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 16:30 ET | Roivant Sciences
Roivant will develop RVT-2001 for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromesRoivant JPM presentation scheduled for Monday, January 10, at 2:15...
FINAL Roivant Logo_Transparent.png
Roivant Sciences Reports Financial Results for the Quarter Ended September 30, 2021 and Provides Business Update
November 15, 2021 07:00 ET | Roivant Sciences, Inc.
Roivant began trading on Nasdaq under “ROIV”; cash balance increased to $2.5 billion.Dermavant announced final results from the Phase 3 PSOARING 3 long-term extension study of tapinarof in patients...
FINAL Roivant Logo_Transparent.png
Roivant to Report Financial Results for the Quarter Ended September 30, 2021 on Monday, November 15, 2021
November 08, 2021 16:45 ET | Roivant Sciences, Inc.
Quarterly investor call and webcast scheduled on Monday, November 15th at 8:00am ETRoivant will also present at the Jefferies London Healthcare and Evercore ISI HealthCONx investor conferences in...
FINAL Roivant Logo_Transparent.png
Roivant Sciences Announces Close of Business Combination with Montes Archimedes Acquisition Corp. and Concurrent PIPE Financing
October 01, 2021 08:00 ET | Roivant Sciences, Inc.
Roivant will begin trading on Nasdaq under the ticker “ROIV” later todayR&D Day presentations from September 28th highlighting Roivant’s pipeline and discovery platform available on Roivant’s...
roivantLogo.png
Roivant Acquires SB742457 From GlaxoSmithKline
December 23, 2014 09:00 ET | Roivant Sciences, Inc.
-Roivant intends to commence Phase 3 clinical trials in Alzheimer's disease in 2015- -Development led by the developer of Alzheimer's medicine, Aricept- HAMILTON, Bermuda, Dec. 23, 2014 (GLOBE...